Expand ASBP Menu
ASBP MENU

ASBP Latest Press Releases

-- December 4, 2025 --

Aspire Biopharma Provides Q3 2025 Business Update ACCESS Newswire 9:00 AM

-- December 2, 2025 --

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) ACCESS Newswire 9:00 AM

-- November 26, 2025 --

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member ACCESS Newswire 9:00 AM

-- November 6, 2025 --

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin ACCESS Newswire 9:00 AM

-- October 6, 2025 --

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform ACCESS Newswire 8:30 AM

-- October 3, 2025 --

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025 ACCESS Newswire 11:30 AM

-- October 1, 2025 --

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication ACCESS Newswire 8:30 AM

-- September 17, 2025 --

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product ACCESS Newswire 8:30 AM

-- September 16, 2025 --

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement ACCESS Newswire 8:30 AM

-- September 3, 2025 --

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) ACCESS Newswire 8:30 AM

-- August 19, 2025 --

Sidoti Events, LLC's Virtual August Micro-Cap Conference ACCESS Newswire 8:00 AM

-- August 18, 2025 --

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) ACCESS Newswire 8:30 AM

-- August 14, 2025 --

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20 ACCESS Newswire 8:00 AM

-- August 13, 2025 --

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World ACCESS Newswire 9:10 AM

-- July 31, 2025 --

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement ACCESS Newswire 8:30 AM

-- July 30, 2025 --

Aspire Biopharma Holdings, Inc. Announces CEO Transition ACCESS Newswire 7:45 PM

-- July 22, 2025 --

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World ACCESS Newswire 10:45 AM

-- July 9, 2025 --

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement ACCESS Newswire 8:30 AM
Market Data Delayed 15 Minutes